Both agents tended to be more effective in p53-wild-type (WT) AML cells (MV4-11 and MOLM-13) than in p53-null AML cells (HL-60, THP-1, and KG-1) (Figure 2A). This evidence concerns the gene TP53 and acute myeloid leukemia.